Anastrozole Tablet
Product Images NDC 43063-383

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 43063-383). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063383 Label (43063383)

This is a medication called Anastozole with a warning not to take it while pregnant. It is important to keep it out of reach of children. The package contains 15 round tablets with each tablet having 1mg of Anastozole. The package insert provides information about dosage and storage. There are specific lot and expiry details mentioned on the package. This medication might have side effects and it is advised to seek medical advice if needed. Contact FDA at 1-800-FDA-1088 to report any side effects. The text also provides dosage information in Spanish.*

FDA Label Image

Anastrozole 01

FDA Label Image

Anastrozole 02

This is a chart showing disease-free survival in months for patients who were randomized to receive treatment with either anastrozole or tamoxifen. The chart displays the proportion of patients who remained alive and disease-free over time. The number of patients at risk for each treatment is listed at the bottom of the chart.*

FDA Label Image

Anastrozole 03

This appears to be a graph or chart showing the proportion of patients alive and disease-free over time based on a randomized treatment of either anastrozole or tamoxifen. The x-axis measures disease-free survival in months, while the y-axis shows the proportion of patients who remain alive and disease-free. The chart also includes a legend indicating which line represents each treatment, as well as a table showing the number of patients at risk for each treatment at various time points.*

FDA Label Image

Anastrozole 04

This is a Kaplan-Meier curve comparing the time to an event (possibly a medical condition) for patients who received either anastrozole or tamoxifen. The graph displays the number of patients at risk at certain time points up to 120 months. However, the text is heavily distorted and contains non-readable characters.*

FDA Label Image

Anastrozole 05

This is a graph displaying the proportion of event-free patients over time in months for a randomized treatment of anastrozole and tamoxifen. The number of patients at risk is also shown. The vertical axis has been truncated to improve clarity.*

FDA Label Image

Anastrozole 06

This appears to be a graph or chart of some kind. The title suggests that the topic is related to a lack of progress, but without more context, it is difficult to determine the specific subject matter.*

FDA Label Image

Anastrozole 07

The information provided is a comparison of two types of treatments, ANASTROZOLE, and TAMOXIFEN, for a condition that is not progressing adequately. The data shows a randomized treatment with measurements over a time of 0 to 6 months with the percentage of people in the study that progress with each treatment. The chart also shows the time to the progression of the treatment in months.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.